Colorectal cancer

VÍCTOR MORENO /RAMON SALAZAR

PRINCIPAL INVESTIGATORS
  • Mercedes Martinez Villacampa
  • Xavier Sole Acha
  • Cristina Santos Vivas
  • Gemma Soler Gonzalez
  • Rebeca Sanz Pamplona
CLINICAL RESEARCHERS
  • Antonio Soriano Izquierdo
  • Francisco Rodriguez Moranta
  • Ferran Losa Gaspa
  • Albert Sueiras Gil
  • Esther Kreisler Moreno
  • Domenico Nicola Fraccalviri
  • Jose Carlos Ruffinelli Rodriguez
  • Nuria Mulet Margalef
POSTDOCTORAL RESEARCHERS (R2)
  • Robert Carreras Torres
  • Marisa Martinez Muñoz
  • Mireia Obon Santacana
  • David Cordero Romera
  • Maria Henar Alonso Aguado
  • Ville Nikolai Pimenoff
  • Ana Isabel Romero Morales
PREDOCTORAL RESEARCHERS (R1)
  • Joan Mas Lloret
  • Virginia Diez Obrero
  • Ania Alay Badosa
  • Sandra Garcia Mulero
  • Sara Hijazo Pechero
  • Ainhoa Garcia Serrano
SCIENTIFIC SUPPORT
  • Nuria Mila Diaz
  • Elisabet Guino Domenech
  • Luisa Carmen De La Peña Negro
  • Daniel Azuara Garcia
  • Susana Lopez Ruiz
  • Anna Diez Villanueva
  • Ferran Moratalla Navarro
  • Pilar Medina Lopez
  • Carmen Rosa Atencia Rojas
  • Jordi Godes Bonet
  • Isabel Padrol Martin
  • Jesus Moreno Castro
  • Adriana Lopez-Doriga Guerra
  • Isela Giro Brinot
MANAGEMENT SUPPORT
  • Adelaida Piera Sancerni
  • Francesc Alarcon Moral
  • Olga Lopez Ciercoles
  • Helena Peña Paris
  • Josipa Bilic Zimmermann
  • Teresa Fuentes Catalan
  • Claudia Lorena Latorre Gaviria
  • Paula Ximena Fernandez Calotti
Cancer
Oncobell

Scientific production

76

PAPERS

33 PUBLICATIONS IN FIRST DECILE

*Average Journal IF

59 PUBLICATIONS IN FIRST QUARTILE

Selected publications:

  • Vermorken J, Cervantes A, Morsing P, Johansson K, Andersson T, Roest NL, Gullbo J, Salazar R . A randomized, multicenter, open-label controlled phase 2 trial of Foxy-5 as neoadjuvant therapy in patients with WNT5A negative colon cancer.. ANNALS OF ONCOLOGY. 10.1093/annonc/mdz155.132
  • Santos C, Azuara D, Viéitez JM, Páez D, Falcó E, Élez E, López-López C, Valladares M, Robles-Díaz L, García-Alfonso P, Bugés C, Durán G, Salud A, Navarro V, Capellá G, Aranda E, Salazar R . Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.. ANNALS OF ONCOLOGY. 10.1093/annonc/mdz082
  • Serra O., Galán M., Ginesta M., Calvo M., Sala N., Salazar R.. Comparison and applicability of molecular classifications for gastric cancer. CANCER TREATMENT REVIEWS. 10.1016/j.ctrv.2019.05.005
  • Ibáñez-Sanz G, Garcia M, Milà N, Hubbard RA, Vidal C, Binefa G, Benito L, Moreno V, Adverse Effects on Colorectal Cancer Screening in Catalonia (EACC) Study Working Group. False-Positive Results in a Population-Based Colorectal Screening Program: Cumulative Risk from 2000 to 2017 with Biennial Screening.. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION. 10.1158/1055-9965.EPI-18-1368
  • Pimenoff VN, Tous S, Benavente Y, Alemany L, Quint W, Bosch FX, Bravo IG, de Sanjosé S . Distinct geographic clustering of oncogenic human papillomaviruses multiple infections in cervical cancers: Results from a worldwide cross-sectional study.. INTERNATIONAL JOURNAL OF CANCER. 10.1002/ijc.31964

Research highlights

PROJECTS

8 Ongoing projects
3 Started projects 

 

14 ongoing clinical trials
4 Started clinical trials

PUBLISHED WORKS

2 Clinical guidelines

Selected projects

  • Genetic and metabolomics screening towards the precision medicine in cancer prevention (1/10/2018 – 30/9/2023) PI: MORENO AGUADO, VICTOR. Funder: ASOCIACION ESPAÑOLA CONTRA EL CANCER.
  • Estudio de las interacciones microbioma-anfitrión para la prevención del cáncer colorrectal (Colonbiome) (1/1/2018 – 31/12/2020) PI: MORENO AGUADO, VICTOR. Funder: FIS-Instituto de Salud Carlos III.
  • Mejora de la selección de pacientes candidatos a terapia anti-EGFR en cáncer colorrectal metastasico: eficacia según los nuevos subtipos moleculares (mesenquimal versus canónico) (1/1/2017 – 30/6/2021) PI: SALAZAR SOLER, RAMON. Funder: FIS-Instituto de Salud Carlos III.
  • Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer (1/1/2016 – 30/5/2020) PI: SALAZAR SOLER, RAMON. Funder: VHIO.
  • Phase II, open-label, single arm, multicenter study of Encorafenib, Binimetinib Plus Cetuximab in subjects with previously untreated BRAFV600E -mutant metastatic colorectal cancer (24/1/2019 – ) PI: RUFFINELLI RODRÍGUEZ, JOSÉ CARLOS. Funder ref.: W00090 GE 2 01.
  • A randomized, multicentre, open-label controlled phase II trial of Foxy-5 as neo-adjuvant therapy in subjects with WNT-5A low colon cancer (5/3/2019 – 5/3/2025) PI: SANTOS VIVAS, CRISTINA. Funder ref.: SMS-0472B.
  • Estudio abierto, aleatorizado, fase 3 comparando Trifluridina/Tipiracilo (S95005) en combinación con Bevacizumab y Capecitabina en combinación con Bevacizumab en primera línea de tratamiento de pacientes con cáncer colorrectal metastásico que no son candidatos a terapia intensiva (Estudio Solstice) (11/6/2019 -) PI: SOLER GONZÁLEZ, GEMMA. Funder ref.: CL3-95005-006 (SOLSTICE).
  • Efectividad y tolerabilidad de ustejinumab en la práctica clínica en pacientes con enfermedad de crohn activa (10/5/2019 – ) PI: RODRIGUEZ MORANTA, FRANCISCO. Funder ref.: JAN-CRD-2018-01 (CNTO1275CRD4028).